Adjustment of Publicis Warrants Conversion Ratio

PARIS--(BUSINESS WIRE)-- Regulatory News:

Publicis Groupe S.A. (Paris: PUB) [Euronext Paris: FR0000130577, CAC 40] informs holders of Publicis share subscription warrants (“BSA”) (ISIN Code: FR0000312928) that the conversion ratio of the warrants is adjusted from 1.116 Publicis share to 1.164 Publicis share per warrant as of July 4, 2022, ex-dividend date.

This adjustment, pursuant to the provisions of paragraph 7.5.8.3. of the information memorandum (note d’opération) (AMF visa no. 02-564 of 16 May 2002, the “Information Memorandum”), results from the portion of the 2021 dividend paid out of reserves and premiums of the Company.

About Publicis Groupe - The Power of One

Publicis Groupe [Euronext Paris FR0000130577, CAC 40] is a global leader in communications. The Groupe is positioned at every step of the value chain, from consulting to execution, combining marketing transformation and digital business transformation. Publicis Groupe is a privileged partner in its clients’ transformation to enhance personalization at scale. The Groupe relies on ten expertise concentrated within four main activities: Communications, Media, Data and Technology. Through a unified and fluid organization, its clients have a facilitated access to all its expertise in every market. Present in over 100 countries, Publicis Groupe employs around 90,000 professionals.

www.publicisgroupe.com | Twitter: @PublicisGroupe | Facebook | LinkedIn | YouTube | Viva la Difference!

View source version on businesswire.com: https://www.businesswire.com/news/home/20220708005468/en/

Publicis Groupe

Delphine Stricker
Corporate Communications
+ 33 (0)6 38 81 40 00
[email protected]

Alessandra Girolami
Investor Relations
+ 33 (0)1 44 43 77 88
[email protected]

Clemence Vermersch
Investor Relations
+ 33 (0)6 75 99 67 51
[email protected]

Source: Publicis Groupe S.A.

You May Also Be Interested In

• TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
• Prime Drink Group Announces Private Placement and Agreed Resolution with Creditors
• Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026